Status:
COMPLETED
FSRT Combined With TMZ for Large BMs: a PSM Study
Lead Sponsor:
Chinese Academy of Medical Sciences
Conditions:
Brain Metastases
Radiotherapy
Eligibility:
All Genders
18+ years
Brief Summary
A propensity- matched study was conducted to investigate the feasibility and safety of adding temozolomide to hypofractionated stereotactic radiotherapy for large brain metastases.
Detailed Description
A previous single arm phase II trial of our institution has shown that HFSRT combined with concurrent TMZ was safe and efficient for patients with BMs of ≥ 6cc in volume. The 1-year local control and ...
Eligibility Criteria
Inclusion
- (1) primary tumor was pathologically diagnosed and brain metastases were confirmed by gadolinium-enhanced magnetic resonance imaging (MRI) ; (2) age 18 years or older (3) KPS ≥60, or KPS ≥50 but symptomatically caused by BMs; (4) the large lesions haven't treated with surgery or SRT.
Exclusion
- (1) KPS \<60 but not caused by BMs; (2) the large lesions have been treated with surgery or SRT.
Key Trial Info
Start Date :
January 1 2016
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2017
Estimated Enrollment :
72 Patients enrolled
Trial Details
Trial ID
NCT03338075
Start Date
January 1 2016
End Date
August 1 2017
Last Update
November 9 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.